BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15272920)

  • 1. BRAF mutations in an Italian cohort of thyroid cancers.
    Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
    Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
    Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
    Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
    Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.
    Smith RA; Salajegheh A; Weinstein S; Nassiri M; Lam AK
    Hum Pathol; 2011 Apr; 42(4):500-6. PubMed ID: 21167555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.
    Lee JH; Lee ES; Kim YS; Won NH; Chae YS
    Pathology; 2006 Jun; 38(3):201-4. PubMed ID: 16753739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma.
    Trovisco V; Soares P; Soares R; Magalhães J; Sá-Couto P; Sobrinho-Simões M
    Hum Pathol; 2005 Jun; 36(6):694-7. PubMed ID: 16021577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
    Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
    Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.